ABREAST OF THE CURVE

09.13.135:48 PM ET

FDA Panel Supports ‘Historic’ Cancer Drug

Pre-surgery breast cancer drug poised for approval.

An FDA federal advisory committee has moved toward approving the first pre-surgery breast cancer drug. The drug, Perjeta, has already been used during late-stage breast cancer; now, it may reduce tumors during the disease’s earlier stages.  If so, tumors—even inoperable ones—would be more amenable to surgery and some treated patients may undergo breast-conserving instead of breast-removal surgery.  “This is a historic moment,” says Dr. Mikkael A. Sekeres, a Cleveland Clinic associate professor and the advisory committee’s chairman. He “hope[s] that women with earlier stages of breast cancer will live longer and better.” However, of the annual 220,000 or so new cases of early-stage breast cancer, only 15,000 American women would be eligible for preoperative Perjeta treatment.

 comments
Get The Daily Beast In Your Inbox
By clicking "Subscribe", you agree to have read the Terms of Use and Privacy Policy
Thank You!
You are now subscribed to the Cheat Sheet. We will not share your email with anyone for any reason
You are now subscribed to the Daily Digest. We will not share your email with anyone for any reason
You are now subscribed to the Daily Digest and Cheat Sheet. We will not share your email with anyone for any reason
Follow The Daily Beast